Blood pressure management strategies and podocyte health

IF 3.2 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

American Journal of Hypertension Pub Date : 2024-09-10 DOI:10.1093/ajh/hpae120

Marharyta Semenikhina, Roy O Mathew, Munsef Barakat, Justin P Van Beusecum, Daria V Ilatovskaya, Oleg Palygin

{"title":"Blood pressure management strategies and podocyte health","authors":"Marharyta Semenikhina, Roy O Mathew, Munsef Barakat, Justin P Van Beusecum, Daria V Ilatovskaya, Oleg Palygin","doi":"10.1093/ajh/hpae120","DOIUrl":null,"url":null,"abstract":"Hypertension (HTN) is one of the key global cardiovascular risk factors, which is tightly linked to kidney health and disease development. Podocytes, glomerular epithelial cells that play a pivotal role in maintenance of the renal filtration barrier, are significantly affected by increased glomerular capillary pressure in HTN. Damage or loss of these cells causes proteinuria, which marks the initiation of the HTN-driven renal damage. It goes without saying that effective BP management should not only mitigate cardiovascular risks but also preserve renal function by protecting podocyte integrity. This review offers a comprehensive examination of current blood pressure (BP) management strategies and their implications for podocyte structure and function and emphasizes strategies for the reduction of proteinuria in HTN. We explore primary and secondary antihypertensive agents, including ACE inhibitors, ARBs, calcium channel blockers, diuretics, as well as newer therapies (SGLT2 blocking and endothelin receptor antagonism), emphasizing their mechanistic roles in safeguarding podocytes and curtailing proteinuria.","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":"44 1","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajh/hpae120","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Hypertension (HTN) is one of the key global cardiovascular risk factors, which is tightly linked to kidney health and disease development. Podocytes, glomerular epithelial cells that play a pivotal role in maintenance of the renal filtration barrier, are significantly affected by increased glomerular capillary pressure in HTN. Damage or loss of these cells causes proteinuria, which marks the initiation of the HTN-driven renal damage. It goes without saying that effective BP management should not only mitigate cardiovascular risks but also preserve renal function by protecting podocyte integrity. This review offers a comprehensive examination of current blood pressure (BP) management strategies and their implications for podocyte structure and function and emphasizes strategies for the reduction of proteinuria in HTN. We explore primary and secondary antihypertensive agents, including ACE inhibitors, ARBs, calcium channel blockers, diuretics, as well as newer therapies (SGLT2 blocking and endothelin receptor antagonism), emphasizing their mechanistic roles in safeguarding podocytes and curtailing proteinuria.

查看原文本刊更多论文

血压管理策略与荚膜健康

高血压（HTN）是全球主要心血管风险因素之一，与肾脏健康和疾病发展密切相关。荚膜细胞是肾小球上皮细胞，在维持肾脏滤过屏障方面发挥着关键作用。这些细胞的损伤或丧失会导致蛋白尿，这标志着高血压导致的肾脏损伤已经开始。不言而喻，有效的血压管理不仅要降低心血管风险，还要通过保护荚膜细胞的完整性来维护肾功能。本综述全面探讨了当前的血压（BP）管理策略及其对荚膜细胞结构和功能的影响，并强调了减少高血压肾病蛋白尿的策略。我们探讨了主要和次要降压药物，包括 ACE 抑制剂、ARB、钙通道阻滞剂、利尿剂以及新型疗法（SGLT2 阻断和内皮素受体拮抗），强调了它们在保护荚膜细胞和减少蛋白尿方面的机制作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Hypertension 医学-外周血管病

CiteScore

6.90

自引率

6.20%

发文量

144

审稿时长

3-8 weeks

期刊介绍： The American Journal of Hypertension is a monthly, peer-reviewed journal that provides a forum for scientific inquiry of the highest standards in the field of hypertension and related cardiovascular disease. The journal publishes high-quality original research and review articles on basic sciences, molecular biology, clinical and experimental hypertension, cardiology, epidemiology, pediatric hypertension, endocrinology, neurophysiology, and nephrology.